{"product_id":"300558sz-business-model-canvas","title":"Betta Pharmaceuticals Co., Ltd. (300558.SZ): Canvas Business Model","description":"\u003cp\u003eIn the dynamic landscape of the pharmaceutical industry, Betta Pharmaceuticals Co., Ltd. stands out with its innovative approach and robust business model. By harnessing strategic partnerships, pioneering research, and a commitment to patient care, Betta navigates challenges while delivering high-quality healthcare solutions. Dive deeper into the intricacies of their Business Model Canvas, exploring how each component interlocks to foster growth and value in an ever-evolving market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003ch3\u003eResearch Institutions Collaboration\u003c\/h3\u003e\n\u003cp\u003eBetta Pharmaceuticals Co., Ltd. actively collaborates with various research institutions to boost its R\u0026amp;D capabilities. For instance, in 2022, they partnered with the Shanghai Institute of Materia Medica to enhance the development of innovative treatments. The partnership budget amounted to approximately \u003cstrong\u003e¥100 million\u003c\/strong\u003e over a three-year period.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers Alliances\u003c\/h3\u003e\n\u003cp\u003eStrategic alliances with healthcare providers are crucial for Betta Pharmaceuticals’ business model. They have entered into agreements with over \u003cstrong\u003e200 hospitals\u003c\/strong\u003e across China to facilitate clinical trials and ensure broader access to their products. These collaborations have resulted in a \u003cstrong\u003e20%\u003c\/strong\u003e increase in patient enrollment for trial studies.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eBetta Pharmaceuticals relies on a robust network of raw material suppliers to maintain product quality and cost-effectiveness. In 2023, the company sourced over \u003cstrong\u003e70%\u003c\/strong\u003e of its raw materials from established suppliers like Zhejiang Jianfeng and Xinjiang Lanjian, ensuring a steady supply chain. The total procurement cost for raw materials in the last fiscal year was approximately \u003cstrong\u003e¥500 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eOrganization\u003c\/th\u003e\n        \u003cth\u003eFinancial Commitment (¥ million)\u003c\/th\u003e\n        \u003cth\u003eYear Established\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institution\u003c\/td\u003e\n        \u003ctd\u003eShanghai Institute of Materia Medica\u003c\/td\u003e\n        \u003ctd\u003e100\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Provider\u003c\/td\u003e\n        \u003ctd\u003eVarious Hospitals\u003c\/td\u003e\n        \u003ctd\u003e0\u003c\/td\u003e\n        \u003ctd\u003eMultiple Years\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Supplier\u003c\/td\u003e\n        \u003ctd\u003eZhejiang Jianfeng\u003c\/td\u003e\n        \u003ctd\u003e250\u003c\/td\u003e\n        \u003ctd\u003eOngoing\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Supplier\u003c\/td\u003e\n        \u003ctd\u003eXinjiang Lanjian\u003c\/td\u003e\n        \u003ctd\u003e250\u003c\/td\u003e\n        \u003ctd\u003eOngoing\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eBetta Pharmaceuticals Co., Ltd. is heavily centered around several key activities that facilitate its operational success in the pharmaceutical industry. Here, we detail these critical actions and processes.\u003c\/p\u003e\n\n\u003ch3\u003eDrug Research and Development\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals invests substantially in drug research and development (R\u0026amp;D). In 2022, the company allocated approximately \u003cstrong\u003e35%\u003c\/strong\u003e of its total revenue towards R\u0026amp;D expenditures, which amounted to around \u003cstrong\u003eCNY 1.08 billion\u003c\/strong\u003e. This investment is instrumental in the discovery and development of new medications, particularly in oncology and autoimmune diseases.\u003c\/p\u003e\n\n\u003cp\u003eThe company focuses on innovative drug formulations and therapeutic methods, with a pipeline that includes over \u003cstrong\u003e20 candidate drugs\u003c\/strong\u003e in various stages of development. Notably, Betta Pharmaceuticals' lead oncology drug, \u003cstrong\u003eBeiGene's Tislelizumab\u003c\/strong\u003e, recorded a growth of \u003cstrong\u003e150%\u003c\/strong\u003e in sales year-over-year, contributing significantly to the R\u0026amp;D initiatives.\u003c\/p\u003e\n\n\u003ch3\u003eClinical Trials Management\u003c\/h3\u003e\n\n\u003cp\u003eClinical trials are a crucial part of Betta's key activities. The company has managed over \u003cstrong\u003e15 clinical trials\u003c\/strong\u003e in the past year alone, focusing primarily on Phase II and III trials. In 2022, the total expenditure on clinical trials was approximately \u003cstrong\u003eCNY 600 million\u003c\/strong\u003e, reflecting the commitment to rigorous testing before bringing products to market.\u003c\/p\u003e\n\n\u003cp\u003eData from the trials indicates an overall success rate of about \u003cstrong\u003e60%\u003c\/strong\u003e in progressing from Phase I to Phase III, which exceeds the industry average of \u003cstrong\u003e30%\u003c\/strong\u003e. This success is attributed to strong partnerships with various research institutions and hospitals.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eNumber of Clinical Trials\u003c\/th\u003e\n    \u003cth\u003eExpenditure on Trials (CNY)\u003c\/th\u003e\n    \u003cth\u003eSuccess Rate (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2020\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n    \u003ctd\u003e400 million\u003c\/td\u003e\n    \u003ctd\u003e55\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e14\u003c\/td\u003e\n    \u003ctd\u003e500 million\u003c\/td\u003e\n    \u003ctd\u003e57\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e15\u003c\/td\u003e\n    \u003ctd\u003e600 million\u003c\/td\u003e\n    \u003ctd\u003e60\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory Approvals\u003c\/h3\u003e\n\n\u003cp\u003eSecuring regulatory approvals is pivotal for Betta Pharmaceuticals. The company has navigated the complexities of regulatory environments in various markets, achieving approvals for \u003cstrong\u003e8 new drugs\u003c\/strong\u003e in 2022. This includes successful filings with the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\n\u003cp\u003eAverage approval timelines for Betta's new drugs have shown improvement, with the latest drugs receiving approval within an average of \u003cstrong\u003e18 months\u003c\/strong\u003e, compared to the industry average of \u003cstrong\u003e24-36 months\u003c\/strong\u003e. This efficiency is vital for maintaining competitive advantages in fast-paced pharmaceutical markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eNew Drug Approvals\u003c\/th\u003e\n    \u003cth\u003eAverage Approval Time (Months)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2020\u003c\/td\u003e\n    \u003ctd\u003e5\u003c\/td\u003e\n    \u003ctd\u003e30\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e7\u003c\/td\u003e\n    \u003ctd\u003e25\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e8\u003c\/td\u003e\n    \u003ctd\u003e18\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn conclusion, Betta Pharmaceuticals Co., Ltd. effectively engages in drug research and development, clinical trials management, and regulatory approvals, all of which are essential to delivering its value proposition to customers whilst ensuring compliance with industry standards.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmaceutical R\u0026amp;D Team:\u003c\/strong\u003e Betta Pharmaceuticals Co., Ltd. employs a dedicated research and development (R\u0026amp;D) team comprising approximately \u003cstrong\u003e1,500\u003c\/strong\u003e researchers, professionals, and technicians. The company has invested over \u003cstrong\u003eCNY 1.5 billion\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 230 million\u003c\/strong\u003e) annually into R\u0026amp;D as of 2023. This investment supports the development of innovative therapies, particularly in oncology and autoimmune diseases, underscoring their commitment to advancing healthcare solutions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatented Technologies:\u003c\/strong\u003e Betta Pharmaceuticals holds numerous patents featuring \u003cstrong\u003eover 100\u003c\/strong\u003e active patents in China and abroad, particularly in the area of monoclonal antibodies and targeted therapies. The company's flagship drug, \u003cstrong\u003eBevacizumab\u003c\/strong\u003e, received a patent extension valid until \u003cstrong\u003e2028\u003c\/strong\u003e, highlighting the strength of its intellectual property portfolio. Recent reports indicate that sales from patented products accounted for \u003cstrong\u003e65%\u003c\/strong\u003e of the company’s total revenue in 2022, contributing approximately \u003cstrong\u003eCNY 4.2 billion\u003c\/strong\u003e (around \u003cstrong\u003eUSD 650 million\u003c\/strong\u003e). \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing Facilities:\u003c\/strong\u003e Betta Pharmaceuticals operates advanced manufacturing facilities located in Jiangsu Province, equipped with state-of-the-art technology that complies with international quality standards, including \u003cstrong\u003eISO 9001\u003c\/strong\u003e and \u003cstrong\u003eGMP\u003c\/strong\u003e certifications. The capacity of these facilities is reported to be capable of producing up to \u003cstrong\u003e10 million units\u003c\/strong\u003e of pharmaceutical products annually. The company is also investing \u003cstrong\u003eCNY 800 million\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 122 million\u003c\/strong\u003e) in a new facility slated to enhance production capabilities and efficiency by \u003cstrong\u003e20%\u003c\/strong\u003e by 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eResource Type\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eInvestment\/Value\u003c\/th\u003e\n        \u003cth\u003eOutcome\/Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Team\u003c\/td\u003e\n        \u003ctd\u003eDedicated team of researchers and professionals\u003c\/td\u003e\n        \u003ctd\u003eCNY 1.5 billion (USD 230 million) annually\u003c\/td\u003e\n        \u003ctd\u003eInnovative therapies development\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatented Technologies\u003c\/td\u003e\n        \u003ctd\u003eActive patents in monoclonal antibodies and targeted therapies\u003c\/td\u003e\n        \u003ctd\u003eOver 100 patents\u003c\/td\u003e\n        \u003ctd\u003e65% of total revenue from patented products\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eState-of-the-art manufacturing facility, compliant with ISO and GMP\u003c\/td\u003e\n        \u003ctd\u003eCNY 800 million (USD 122 million) for new facility\u003c\/td\u003e\n        \u003ctd\u003eProduction capacity increase of 20% by 2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eBetta Pharmaceuticals Co., Ltd. is recognized for its innovative pharmaceutical offerings. The company's value propositions create a robust framework for delivering exceptional solutions to meet diverse patient needs.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative Drug Solutions\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals invests heavily in research and development (R\u0026amp;D). In 2022, the company's R\u0026amp;D expenditure reached approximately \u003cstrong\u003e¥900 million\u003c\/strong\u003e, accounting for about \u003cstrong\u003e15%\u003c\/strong\u003e of its total revenue. This focus on innovation has resulted in a strong pipeline of new drugs. As of October 2023, Betta has over \u003cstrong\u003e15 drugs\u003c\/strong\u003e in various phases of clinical trials, with particular emphasis on oncology and autoimmune disorders.\u003c\/p\u003e\n\n\u003ch3\u003eHigh Efficacy Treatments\u003c\/h3\u003e\n\n\u003cp\u003eBetta's commitment to high efficacy is evident in its flagship product, \u003cstrong\u003ePD-1 inhibitor\u003c\/strong\u003e (a key player in cancer treatment). In 2022, the drug reported annual sales exceeding \u003cstrong\u003e¥3 billion\u003c\/strong\u003e. This represented a year-over-year growth rate of \u003cstrong\u003e25%\u003c\/strong\u003e. Clinical trials have shown an overall response rate of around \u003cstrong\u003e30%\u003c\/strong\u003e, positioning Betta’s treatments among the leading options in the market.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSales (2022)\u003c\/th\u003e\n\u003cth\u003eGrowth Rate\u003c\/th\u003e\n\u003cth\u003eOverall Response Rate\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePD-1 Inhibitor\u003c\/td\u003e\n\u003ctd\u003e¥3 billion\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative Rheumatoid Arthritis Treatment\u003c\/td\u003e\n\u003ctd\u003e¥1.2 billion\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Antiviral Treatment\u003c\/td\u003e\n\u003ctd\u003e¥500 million\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003ePatient-Focused Healthcare\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals has cultivated a patient-centric model by providing comprehensive support services. The company has established over \u003cstrong\u003e200 patient assistance programs\u003c\/strong\u003e to help individuals access necessary medications without financial hardship. According to a survey conducted in 2023, over \u003cstrong\u003e70%\u003c\/strong\u003e of patients reported high satisfaction with the support services, indicating an alignment between Betta’s offerings and patient needs.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, Betta's digital health initiatives, including a telemedicine platform launched in 2022, have reached over \u003cstrong\u003e500,000 active users\u003c\/strong\u003e, reflecting a growing shift towards convenient healthcare access. By 2023, this platform facilitated over \u003cstrong\u003e100,000 consultations\u003c\/strong\u003e, further enhancing the company's patient engagement strategy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eInitiative\u003c\/th\u003e\n\u003cth\u003eStatistics (2023)\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Assistance Programs\u003c\/td\u003e\n\u003ctd\u003e200+ programs\u003c\/td\u003e\n\u003ctd\u003eHigh patient satisfaction (70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelemedicine Platform\u003c\/td\u003e\n\u003ctd\u003e500,000 active users\u003c\/td\u003e\n\u003ctd\u003e100,000 consultations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThrough these strategic value propositions, Betta Pharmaceuticals Co., Ltd. effectively addresses customer needs, fostering a competitive edge in the dynamic pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eBetta Pharmaceuticals Co., Ltd. emphasizes strong customer relationships as a cornerstone of its business model. The company engages with various stakeholders in the healthcare ecosystem, primarily focusing on healthcare professionals, patient support, and dedicated customer service.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Engagement with Healthcare Professionals\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals maintains a proactive approach in engaging healthcare professionals. In 2022, the company reported having over \u003cstrong\u003e2,000 field sales representatives\u003c\/strong\u003e who interact directly with doctors and pharmacists to provide information about their pharmaceutical products. This engagement ensures that healthcare providers are well-informed about the latest therapeutic advancements and product offerings.\u003c\/p\u003e\n\n\u003cp\u003eAccording to a market analysis, Betta Pharmaceuticals’ market penetration has increased by \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year, largely attributed to effective communication and relationship-building initiatives with healthcare professionals.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Service\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals offers dedicated customer service to enhance user experience and address the needs of healthcare practitioners. Their customer service department operates with more than \u003cstrong\u003e150 dedicated agents\u003c\/strong\u003e, handling inquiries and providing support across various platforms, including phone, email, and web chat.\u003c\/p\u003e\n\n\u003cp\u003eIn 2023, Betta Pharmaceuticals achieved a customer satisfaction rate of \u003cstrong\u003e92%\u003c\/strong\u003e, as reported in their annual customer service review. This reflects their commitment to resolving issues promptly and effectively, thus retaining a loyal customer base.\u003c\/p\u003e\n\n\u003ch3\u003ePatient Support Programs\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals has established multiple patient support programs aimed at enhancing medication adherence and overall patient health. In 2022, the company invested over \u003cstrong\u003e$3 million\u003c\/strong\u003e into these programs, benefiting approximately \u003cstrong\u003e100,000 patients\u003c\/strong\u003e across various therapeutic areas. These programs provide resources such as medication guides, financial assistance, and counseling services.\u003c\/p\u003e\n\n\u003cp\u003eThe effectiveness of patient support initiatives is evidenced by a reported increase in treatment adherence rates, which are estimated at \u003cstrong\u003e85%\u003c\/strong\u003e among participants in these programs, compared to a national average of \u003cstrong\u003e70%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer Relationship Aspect\u003c\/th\u003e\n\u003cth\u003eMetrics\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField Sales Representatives\u003c\/td\u003e\n\u003ctd\u003e2,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Penetration Increase (YoY)\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDedicated Customer Service Agents\u003c\/td\u003e\n\u003ctd\u003e150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Satisfaction Rate\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment in Patient Support Programs\u003c\/td\u003e\n\u003ctd\u003e$3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Benefited\u003c\/td\u003e\n\u003ctd\u003e100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment Adherence Rate (Support Program)\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNational Average Treatment Adherence Rate\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these multifaceted approaches, Betta Pharmaceuticals Co., Ltd. not only aims to acquire and retain customers but also enhances the overall healthcare experience for both professionals and patients alike. The focus on robust customer relationships ultimately drives growth and fosters brand loyalty within a competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eBetta Pharmaceuticals employs a multi-faceted approach in its channels strategy to effectively communicate with and deliver its value proposition to customers. This includes leveraging distributor networks, a direct sales force, and online pharmaceutical platforms.\u003c\/p\u003e\n\n\u003ch3\u003eDistributor Networks\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals works with a wide range of distributor networks to expand its market reach. In the fiscal year 2023, Betta’s distribution network included over \u003cstrong\u003e300\u003c\/strong\u003e distributors across China. These partnerships have allowed the company to capture a significant share of the market, with reports indicating that about \u003cstrong\u003e70%\u003c\/strong\u003e of its sales volume is attributed to distributors.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\n\u003cp\u003eThe company has established a robust direct sales force comprising approximately \u003cstrong\u003e1,500\u003c\/strong\u003e sales representatives who are dedicated to promoting their products directly to hospitals and clinics. This direct approach has resulted in a sales growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-on-year as of Q3 2023. The productivity of the sales force is noted through an average sales volume per representative of approximately \u003cstrong\u003e$250,000\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Pharmaceutical Platforms\u003c\/h3\u003e\n\n\u003cp\u003eWith the rise of e-commerce, Betta Pharmaceuticals has also tapped into online pharmaceutical platforms. As of 2023, online sales accounted for approximately \u003cstrong\u003e25%\u003c\/strong\u003e of their total revenue, reflecting a growth trend in digital channel usage. Major collaborations with platforms such as JD Health and Alibaba Health have significantly enhanced their digital presence. The revenue from online channels is projected to grow by \u003cstrong\u003e20%\u003c\/strong\u003e in the next fiscal year.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel Type\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eImpact on Sales (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistributor Networks\u003c\/td\u003e\n        \u003ctd\u003e300+ distributors\u003c\/td\u003e\n        \u003ctd\u003e70%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n        \u003ctd\u003e1,500 sales representatives\u003c\/td\u003e\n        \u003ctd\u003e15% Year-on-Year Growth\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Pharmaceutical Platforms\u003c\/td\u003e\n        \u003ctd\u003e25% of total revenue\u003c\/td\u003e\n        \u003ctd\u003e20% Projected Growth\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, Betta Pharmaceuticals' channels are designed to maximize reach while adapting to the evolving landscape of pharmaceutical sales, with a mix of traditional and digital strategies effectively supporting its operational goals.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eBetta Pharmaceuticals Co., Ltd. targets several distinct customer segments to effectively meet diverse healthcare needs. This strategic segmentation enables the company to tailor its offerings and enhance customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\n\u003cp\u003eBetta Pharmaceuticals supplies a range of medications and healthcare products to hospitals and clinics. In China, the hospital sector accounted for approximately \u003cstrong\u003e35%\u003c\/strong\u003e of total healthcare expenditure in 2021, indicating a substantial opportunity for pharmaceutical companies. In 2022, the total number of hospitals in China was reported at around \u003cstrong\u003e34,000\u003c\/strong\u003e, comprising public and private institutions. Betta's focus on quality and innovation has positioned it well within this segment, contributing to an estimated annual revenue growth of \u003cstrong\u003e10%\u003c\/strong\u003e from hospital sales in recent years.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Healthcare Professionals\u003c\/h3\u003e\n\n\u003cp\u003ePharmacies, both retail and online, form a critical customer segment for Betta Pharmaceuticals. In 2022, the retail pharmacy market in China was valued at approximately \u003cstrong\u003eUSD 116.4 billion\u003c\/strong\u003e, with an expected CAGR of \u003cstrong\u003e6.4%\u003c\/strong\u003e from 2023 to 2030. Betta Pharmaceuticals collaborates with over \u003cstrong\u003e5,000\u003c\/strong\u003e pharmacies, ensuring broad distribution of its products. Moreover, Betta leverages relationships with healthcare professionals to enhance its market presence, with around \u003cstrong\u003e70%\u003c\/strong\u003e of prescriptions being influenced by physician recommendations.\u003c\/p\u003e\n\n\u003ch3\u003ePatients with Chronic Conditions\u003c\/h3\u003e\n\n\u003cp\u003ePatients suffering from chronic conditions are a vital customer segment for Betta Pharmaceuticals. The World Health Organization (WHO) reported that chronic diseases account for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total deaths globally, with the prevalence of such conditions in China increasing annually. In 2021, an estimated \u003cstrong\u003e300 million\u003c\/strong\u003e people were living with chronic diseases in China, representing a significant market opportunity. Betta's portfolio includes specialized treatments targeting diabetes, cardiovascular diseases, and respiratory conditions, contributing to an estimated \u003cstrong\u003e25%\u003c\/strong\u003e share of its total sales in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eMarket Size (2022)\u003c\/th\u003e\n    \u003cth\u003eEstimated Revenue Growth\u003c\/th\u003e\n    \u003cth\u003eKey Products\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n    \u003ctd\u003eUSD 35 billion\u003c\/td\u003e\n    \u003ctd\u003e10%\u003c\/td\u003e\n    \u003ctd\u003eInjectables, Antivirals\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmacies and Healthcare Professionals\u003c\/td\u003e\n    \u003ctd\u003eUSD 116.4 billion\u003c\/td\u003e\n    \u003ctd\u003e6.4%\u003c\/td\u003e\n    \u003ctd\u003ePrescription Medications, OTC Products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatients with Chronic Conditions\u003c\/td\u003e\n    \u003ctd\u003eMarket Size ~USD 30 billion\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003eDiabetes Medications, Cardiovascular Drugs\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eBy understanding and addressing the unique needs of these customer segments, Betta Pharmaceuticals can deliver targeted solutions and enhance its competitive edge in the pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eBetta Pharmaceuticals invests significantly in research and development to innovate and enhance its product offerings. For the fiscal year 2022, R\u0026amp;D expenses were reported at approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, accounting for about \u003cstrong\u003e30%\u003c\/strong\u003e of total revenue. This level of investment allows Betta to maintain a competitive edge in the biopharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eManufacturing costs comprise a large portion of Betta's overall expenditure. In 2022, the company's manufacturing costs totaled around \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e. This figure includes raw materials, labor, and overhead costs associated with producing their pharmaceutical products. The manufacturing cost per unit averaged \u003cstrong\u003eRMB 25\u003c\/strong\u003e during this period.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\u003cp\u003eMarketing and distribution costs are critical for ensuring product visibility and market penetration. Betta Pharmaceuticals allocated approximately \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e for marketing and distribution in 2022, representing about \u003cstrong\u003e15%\u003c\/strong\u003e of total operational costs. The company employs various channels for distribution, including direct sales to hospitals and pharmacies, alongside partnerships with distributors.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003e2022 Spending (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.2 Billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.5 Billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e37.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Distribution\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e600 Million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOther Operational Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e700 Million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e17.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe focus on R\u0026amp;D ensures that Betta Pharmaceuticals remains at the forefront of innovation, while sustainable manufacturing practices contribute to cost efficiency. Furthermore, strategic marketing and distribution efforts are essential for optimizing revenue streams and expanding market reach.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBetta Pharmaceuticals Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Pharmaceutical Sales\u003c\/h3\u003e\n\u003cp\u003eBetta Pharmaceuticals generates a significant portion of its revenue through direct sales of pharmaceutical products. In the fiscal year 2022, the total revenue from direct sales amounted to \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e, reflecting a growth of \u003cstrong\u003e15%\u003c\/strong\u003e from 2021. The company focuses on onco-therapeutics, with major products including the cancer treatment drug, \u003cstrong\u003eBevacizumab\u003c\/strong\u003e, which alone contributed to over \u003cstrong\u003e30%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eThe company has successfully entered into various licensing agreements that supplement its revenue streams. In 2022, the licensing revenue reached approximately \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e, primarily from partnerships with international firms for the development of new oncology drugs. Noteworthy is the agreement with a prominent global pharmaceutical company in 2021, which is expected to yield around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e annually over the next five years.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Grants and Funding\u003c\/h3\u003e\n\u003cp\u003eBetta Pharmaceuticals actively pursues research grants and funding opportunities to support its development pipeline. In 2022, the company received \u003cstrong\u003eRMB 250 million\u003c\/strong\u003e in grants from various government entities and healthcare organizations. This funding plays a crucial role in financing the research and development of new treatments, with aims for expanding its oncology portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (RMB)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (%)\u003c\/th\u003e\n        \u003cth\u003eKey Products\/Services\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Pharmaceutical Sales\u003c\/td\u003e\n        \u003ctd\u003e3.5 billion\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003eBevacizumab, other oncology treatments\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n        \u003ctd\u003e800 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eVarious oncology drug partnerships\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Grants and Funding\u003c\/td\u003e\n        \u003ctd\u003e250 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eGovernment and healthcare organization grants\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45679887155349,"sku":"300558sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/300558sz-business-model-canvas.png?v=1739126285","url":"https:\/\/dcf-model.com\/products\/300558sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}